Trial · NCT01340937
Results by group266
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 266
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen | V419 Lot A | 5.51 | 95% Confidence Interval 4.88 to 6.21 | µg/mL | |
| Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen | V419 Lot B | 6.10 | 95% Confidence Interval 5.38 to 6.92 | µg/mL | |
| Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen | V419 Lot C | 6.59 | 95% Confidence Interval 5.80 to 7.47 | µg/mL | |
| Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen | Control | 3.76 | 95% Confidence Interval 3.11 to 4.55 | µg/mL | |
| Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen | V419 Lots A, B, and C Combined | 6.05 | 95% Confidence Interval 5.63 to 6.50 | µg/mL | |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | V419 Lot A | Titer >=1 µg/mL | 86.75 | 95% Confidence Interval 83.79 to 89.36 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | V419 Lot B | Titer >=1 µg/mL | 87.25 | 95% Confidence Interval 84.30 to 89.82 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | V419 Lot C | Titer >=1 µg/mL | 88.40 | 95% Confidence Interval 85.55 to 90.86 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | Control | Titer >=1 µg/mL | 79.51 | 95% Confidence Interval 74.39 to 84.02 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | V419 Lots A, B, and C Combined | Titer >=1 µg/mL | 87.47 | 95% Confidence Interval 85.84 to 88.96 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | V419 Lot A | Titer >=0.15 µg/mL | 99.01 | 95% Confidence Interval 97.85 to 99.63 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | V419 Lot B | Titer >=0.15 µg/mL | 98.32 | 95% Confidence Interval 96.94 to 99.19 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | V419 Lot C | Titer >=0.15 µg/mL | 97.82 | 95% Confidence Interval 96.29 to 98.83 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | Control | Titer >=0.15 µg/mL | 96.18 | 95% Confidence Interval 93.27 to 98.08 | Percentage of participants |
| Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen | V419 Lots A, B, and C Combined | Titer >=0.15 µg/mL | 98.38 | 95% Confidence Interval 97.69 to 98.92 | Percentage of participants |
| Geometric Mean Concentration of Antibodies to Hepatitis B Surface Antigen | V419 Lot A | 1195.96 | 95% Confidence Interval 1081.62 to 1322.39 | mIU/mL | |
| Geometric Mean Concentration of Antibodies to Hepatitis B Surface Antigen | V419 Lot B | 1376.86 | 95% Confidence Interval 1264.74 to 1498.92 | mIU/mL | |
| Geometric Mean Concentration of Antibodies to Hepatitis B Surface Antigen | V419 Lot C | 1414.52 | 95% Confidence Interval 1297.52 to 1542.06 | mIU/mL | |
| Geometric Mean Concentration of Antibodies to Hepatitis B Surface Antigen | Control | 609.08 | 95% Confidence Interval 515.29 to 719.93 | mIU/mL | |
| Geometric Mean Concentration of Antibodies to Diphtheria Toxin | V419 Lot A | 0.37 | 95% Confidence Interval 0.34 to 0.40 | IU/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01340937/results